The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPjsc Tatneft Regulatory News (ATAD)

  • This share is currently suspended. It was suspended at a price of 2.35

Share Price Information for Pjsc Tatneft (ATAD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.35
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2.35
ATAD Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Financial Report

1 Apr 2015 16:04

RNS Number : 2263J
OAO Tatneft
01 April 2015
 



Tatneft published its audited IFRS consolidated financial statements for the year ended December 31, 2014.

 

01 April 2015

 

OAO Tatneft (the "Company") announces today that it published on its web-site (http://www.tatneft.ru/?lang=en) the audited consolidated financial statements for the year ended 31 December 2014 prepared in accordance with International Financial Reporting Standards ("IFRS") (the "Financial Statements") and related Directors' report, incorporating Management Discussion and Analysis of Results of Operations (the "MD&A").

 

Selected financial highlights below are based on the respective IFRS financial statements of the Company. These highlights do not replace the Financial Statements or the MD&A and all interested persons are encouraged to read these documents for full understanding of 2014 IFRS results. Russian Ruble amounts below have been translated into U.S. Dollars, for sales and other operating revenues and net profit at the average exchange rate during the respective reporting period and for items of Statements of Financial Position at the exchange rate on the last date of the respective reporting period.

 

The Company's consolidated sales and other operating revenues net of export duties and excise tax in 2014 were 476,360 million Rubles (US$ 12,399 million) as compared to 454,983 million Rubles (US$ 14,285 million) in 2013. The consolidated profit attributable to Group shareholders in 2014 was 92,227 million Rubles (US$ 2,400 million) as compared to 70,832 million Rubles (US$ 2,224 million) in 2013.

 

Total consolidated assets of the Company increased from 674,089 million Rubles (US$ 20,595 million) as of 31 December 2013, to 732,934 million Rubles (decreased in US dollar terms to US$ 13,028 million) as of 31 December 2014.

 

Total consolidated liabilities of the Company decreased from 170,107 million Rubles (US$ 5,197 million) as of 31 December 2013, to 150,690 million Rubles (US$ 2,678 million) as of 31 December 2014.

 

Total consolidated shareholders' equity increased from 503,982 million Rubles (US$ 15,398 million) as of 31 December 2013, to 582,244 million Rubles (decreased in US dollar terms to US$ 10,349 million) as of 31 December 2014.

 

The Company's representatives will discuss the IFRS financial highlights for the year ended 31 December 2014 on conference call on 2 April 2015 at 16:00 Moscow time, 14:00 London time, 09:00am New York time.

 

To participate in the conference call, please dial any of the following numbers*:

 

United Kingdom: 0800 068 0521;

USA: +1 855 442 0876;

Russia: 8 800 100 9635;

All other locations: +44 203 478 5921

 

Password to gain access to the conference call is "Tatneft".

 

The conference call replay will be available until 2 May 2015 completion of the call by dialing* +44 121 260 4861 (international dial-in) or +1 866 268 1947 (USA), using Conference ID 0573275 and followed by the # sign.

 

* JSC Tatneft shall not be liable for inability to use any of the free numbers.

 

Forward-looking statements: These materials contain statements about future events and expectations that are forward-looking in nature. Any statement in these materials that is not a statement of historical fact is a forward-looking statement that involves known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements expressed or implied by such forward-looking statements to differ. OAO Tatneft assumes no obligations to update the forward-looking statements contained herein to reflect actual results, changes in assumptions or changes in factors affecting these statements.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSLLFIESFILIIE
Date   Source Headline
29th Dec 202311:41 amRNSEGM Approves Dividends for 9m 2023
21st Nov 20233:18 pmRNSTatneft EGM to approve 9m 2023 dividend
29th Sep 20239:42 amRNSTatneft EGM approves 6m 2023 dividend
15th Aug 20233:21 pmRNSBoard of Directors 1H 2023 div and EGM decisions
30th Jun 20232:44 pmRNSPJSC Tatneft AGM Results
19th Jun 20238:33 amRNSNotice of AGM
27th Apr 202312:20 pmRNSAGM Notice and Dividend Recommendation
30th Mar 20232:15 pmRNSAcquisition of business from Nokian Tyres plc
20th Mar 20237:00 amRNSTatneft's Annual IFRS and Directors' Report
28th Dec 20227:00 amRNSResult of EGM
16th Nov 20227:24 amRNSBoard Recommends Dividends for 9m2022
28th Oct 20224:16 pmRNSTatneft to acquire Russian assets of Nokian Tyres
23rd Sep 202210:09 amRNSTatneft EGM Approves Dividends for 1H2022
30th Aug 20227:00 amRNSTatneft publishes IFRS results for 1H2022
16th Aug 20229:52 amRNSBoard convenes EGM and recommends dividends 1H2022
9th Aug 202211:42 amRNSNew Legal Regime for ADR Holders
24th Jun 20224:35 pmRNSResult of AGM
15th Jun 20223:29 pmRNSPayments to Governments Report 2021
31st May 20229:45 amRNSStatement regarding 1Q 2022 IFRS accounts
23rd May 20222:40 pmRNSBoard Recommends Dividends
17th May 202210:32 amRNSTatneft Obtained Permit to Continue ADR Program
16th May 20228:46 amRNSTatneft Sells Tire Business
29th Apr 20222:04 pmRNSBoard Reapproves Nominations to the Board
27th Apr 202212:28 pmRNSNotice to ADR Holders
25th Apr 20225:24 pmRNSBoard Approves AGM Agenda, Related Issues
19th Apr 202211:10 amRNSLaw Affecting ADR Program - Correction
19th Apr 20229:22 amRNSLaw Affecting ADR Program
1st Apr 20223:10 pmRNSDraft Law; Rating Withdrawal
15th Mar 20228:31 amRNSAnnual Financial Report
14th Mar 202210:06 amRNSStatement regarding Ratings
10th Mar 20223:18 pmRNSBoard Approves Nominations
2nd Mar 20224:41 pmRNSSecond Price Monitoring Extn
2nd Mar 20224:36 pmRNSPrice Monitoring Extension
1st Mar 20224:43 pmRNSSecond Price Monitoring Extn
1st Mar 20224:37 pmRNSPrice Monitoring Extension
28th Feb 20224:41 pmRNSSecond Price Monitoring Extn
28th Feb 20224:37 pmRNSPrice Monitoring Extension
30th Dec 20211:34 pmRNSResult of EGM - Dividends
20th Dec 20219:26 amRNSNew Committee of the Board
30th Nov 202112:35 pmRNSPresentation to Investors
29th Nov 20217:32 amRNS3rd Quarter Results
23rd Nov 20218:03 amRNSBoard Recommends 3Q Dividends
1st Oct 202110:05 amRNSDividend Declaration
27th Aug 20217:25 amRNSHalf-year Report
26th Aug 202110:19 amRNSBoard convenes EGM, recommends dividends
1st Jul 20217:00 amRNSFirst Board Meeting and Board Committees Election
30th Jun 20215:15 pmRNSPayments to Governments Report
25th Jun 20215:10 pmRNSResult of AGM
9th Jun 20212:37 pmRNSAcquisition of EkoPet
4th Jun 20217:30 amRNS1st Quarter Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.